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Acute inflammation is part of the complex re­
sponse to tissue injury and infection by invad­
ing microorganisms. In the initial phase of the 
acute inflammatory response, immune cells ex­
travasate and migrate to the site of inflam­
mation guided by chemokines and eicosanoid 
mediators (Serhan et al., 2008; Tabas and Glass, 
2013). In the resolution phase, specialized lipid 
mediators (SPM) endowed with novel pro­
resolving properties are biosynthesized, which 
stimulates active resolution of tissue insult (Serhan 
and Savill, 2005). The resolution phase limits 
excessive neutrophil infiltration into affected 
organs, namely cessation of PMN influx and 
the clearance of apoptotic PMN and cellular 
debris by macrophages (M; Serhan and Savill, 
2005). Excessive PMN within tissues can give 
rise to sustained local inflammation via further 
tissue destruction that often leads to the even­
tual loss of organ function (Asfaha et al., 2001; 
Serhan and Savill, 2005; Charo and Ransohoff, 
2006; Tabas and Glass, 2013).
Neuronal guidance proteins present in pe­
ripheral tissues contribute to the local control 
of leukocyte migration and inflammation (Wu 
et al., 2001; Rao et al., 2002; Mirakaj et al., 2011a). 
Netrin­1 is one of these neuronal proteins, which 
acts as a chemoattractant in axonal migration 
(Colamarino and Tessier­Lavigne, 1995; van 
Gils et al., 2012). Recently, netrin­1 was found 
to direct leukocyte traffic during acute inflam­
mation in peripheral organs (Ly et al., 2005; 
Rosenberger et al., 2009; Mirakaj et al., 2010, 
2011b; Aherne et al., 2012). With an acute   
inflammatory response, complete resolution of 
tissue inflammation is the ideal outcome for af­
fected tissues to regain function (Bannenberg   
et al., 2005; Serhan and Savill, 2005; Serhan and 
Petasis, 2011). Although netrin­1 clearly exerts 
antiinflammatory and protective properties (Ly 
et al., 2005; Rosenberger et al., 2009; Mirakaj   
et al., 2010, 2011b; Aherne et al., 2012), whether   
netrin­1 serves to stimulate endogenous resolution 
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Resolution of inflammation is now recognized as a biosynthetically active process involving 
pro-resolving mediators. Here, we show in zymosan-initiated peritoneal inflammation that 
the vagus nerve regulates local expression of netrin-1, an axonal guidance molecule that 
activates resolution, and that vagotomy reduced local pro-resolving mediators, thereby 
delaying resolution. In netrin-1+/ mice, resolvin D1 (RvD1) was less effective in reducing 
neutrophil influx promoting resolution of peritonitis compared with Ntn1+/+. Netrin-1 
shortened the resolution interval, decreasing exudate neutrophils, reducing proinflamma-
tory mediators, and stimulating the production of resolvins, protectins, and lipoxins. Human 
monocytes incubated with netrin-1 produced proresolving mediators, including resolvins 
and lipoxins. Netrin-1 and RvD1 displayed bidirectional activation in that they stimulated 
each other’s expression and enhanced efferocytosis. These results indicate that the vagus 
nerve regulates both netrin-1 and pro-resolving lipid mediators, which act in a bidirec-
tional fashion to stimulate resolution, and provide evidence for a novel mechanism for local 
neuronal control of resolution.
© 2014 Mirakaj et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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exudates,  pro­resolving  mediators  are  present,  e.g.,  RvD1, 
LXA4, and PD1 (Fig. 2 B). These were sharply reduced in ex­
udates from vagotomized mice throughout the time course 
(Fig. 2 C and Table 1). These exudates normally resolve by 
24 h, as observed in sham­operated control mice (Fig. 2 C 
inset and Table S1).
Because vagotomy reduced RvD1 levels, we tested whether 
RvD1 could rescue the hyperinflammatory response obtained 
with vagotomy. Indeed, results in Fig. 3 indicate that adminis­
tration of RvD1 rescued the excessive increased PMN infiltra­
tion that resulted from vagotomy (caused by vagus nerve 
cutting). RvD1 stopped PMN influx in the vagotomized ani­
mals and regulated the exudate monocyte recruitment (Fig. 3 A). 
In these exudates, RvD1 also reduced TNF, IL­6, KC (IL­8 in 
humans), MIP­1, and HMGB­1 (Fig. 3 B). Also, netrin­1 re­
duced Ri when given at either T0 (Fig. 4 A) or at the maximum 
PMN infiltration (Fig. 4 B). In both cases, netrin­1 shortened 
the time required to resolve inflammation.
RvD1 pro-resolving capacity is reduced in Ntn1+/ mice
To examine potential interactions between netrin­1 and RvD1, 
we used Ntn1+/+ and Ntn1+/ mice in a peritonitis model. 
First, we determine the endogenous impact of netrin­1 and 
quantified the process in the resolution of acute inflammation 
by performing the resolution indices up to 48 h. The results 
from this demonstrated a delay in resolution with an increase of 
the resolution interval (Ri) by up to 2 h in Ntn1+/ mice com­
pared with Ntn1+/+. The administration of RvD1 shortened 
the Ri in WT mice, whereas this action was not found with 
netrin­1–deficient mice, suggesting that the action of RvD1   
in vivo in this system is mediated at least in part via endogenous 
netrin­1 (Fig. 4, C and D).
Vagotomy reduces netrin-1 expression in pulmonary nerves
As we considered that the netrin­1 expression is likely regu­
lated neuronally, we performed immunochemistry staining of 
lungs from vagotomized or sham­operated mice to determine 
netrin­1 expression. We identified reduced expression of   
netrin­1 within lungs from vagotomized mice, especially on 
neurofilament structures (Fig. 5 A).
Netrin-1 is expressed in immunocompetent cells
To clarify the source of netrin­1 during inflammation, we 
determined the netrin­1 expression in immunocompetent 
cells. We found robust expression of netrin­1 in leukocyte 
subsets including CD15+ granulocytes, CD14+ monocytes, 
CD68+ M, some CD3+ T lymphocytes, and CD19+ B lym­
phocytes (Fig. 5 B).
Netrin-1 enhances pro-resolving lipid mediator biosynthesis
Because SPM play pivotal roles activating resolution circuits 
(Serhan and Savill, 2005; Serhan and Petasis, 2011), to de­
termine whether netrin­1 impacts SPM biosynthesis during 
inflammation–resolution, we performed LC­MS/MS–based 
profiling with inflammatory exudates. In these, netrin­1 in­
creased protectin D1 (PD1) and resolvin D5 (RvD5; Fig. 6). 
Netrin­1 also significantly increased 15­HETE and 12­HETE 
programs remained to be explored. In this regard, resolution 
and eventual homeostasis are achieved via limiting further in­
filtration of neutrophils (PMN), as well as promoting local 
clearance via M phagocytosis of cellular debris, apoptotic 
cells, and/or invading organisms (Serhan and Savill, 2005) or­
chestrated by novel local chemical mediators, i.e., resolvins, that 
possess this defining action (Serhan et al., 2002; Serhan and 
Petasis, 2011). Tracey (2002) uncovered neuronal reflex circuits 
that sense peripheral inflammation and provide regulatory 
feedback via specific nervous signals that regulate immune re­
sponses (Olofsson et al., 2012).
Because it is now clear that endogenous antiinflammation and 
pro­resolution are not equivalent processes in that pro­resolving 
mediators both stop/limit PMN entry and enhance nonphlogis­
tic phagocytosis by M (Serhan and Savill, 2005; Serhan and 
Petasis, 2011), we questioned whether the vagus nerve, netrin­1 
expression, and local endogenous resolution programs are linked 
and impact the resolution of acute inflammation. Here, we re­
port a new circuit involving the vagus nerve, netrin­1, and local 
lipid mediators that control the resolution of inflammation.
RESULTS
Vagotomy regulates netrin and resolution of inflammation
Because vagotomy regulates the magnitude of the inflamma­
tory response (Tracey, 2002), we assessed the impact of vagot­
omy on netrin­1 expression and in peritonitis. To this end, 
C57BL/6 mice were subjected to unilateral vagotomy (or a 
comparable sham surgical procedure) 7 d before initiating in­
flammation. Using Western blot analysis, we determined that 
in vagotomized mice, netrin­1 mRNA expression was signifi­
cantly reduced in organs innervated by the vagus nerve, such 
as the lung and the peritoneum (Fig. 1), and protein expression 
was reduced as well. Of interest, during peritonitis, total exudate 
leukocyte numbers, PMN, and the marker myeloperoxidase 
were significantly increased in vagotomized mice following 
challenge compared with sham­operated mice (data not shown). 
Determination of the resolution indices (Bannenberg et al., 
2005) in vagotomized animals demonstrated a clear delay in res­
olution, with an increase in the resolution interval from Ri = 
24 h to Ri = 37 h (Fig. 1 C); also, proinflammatory cytokine and 
chemokine levels were elevated in inflammatory exudates from 
vagotomized mice compared with sham mice (Fig. 1 D).
Acetylcholine,  the  principal  neurotransmitter  involved   
in the inflammatory reflex, and netrin­1 were both significantly 
attenuated in exudates from vagotomized animals (Fig. 1,   
E and F). Together, these findings suggest that vagotomy regu­
lates the resolution interval, leukocyte exudate cell numbers, 
chemokines, and cytokines and that netrin­1 is involved in this 
neuronal–inflammatory–resolution circuit.
Vagotomy impacts resolution programs: rescue with RvD1
Vagotomy shifted the profile of lipid mediators to increase the 
proinflammatory mediators, i.e., leukotriene B4 (Fig. 2), and 
decrease the pro­resolving mediators such as RvD1 in exudates. 
Each mediator was identified using LC­MS­MS–based me­
tabololipidomics and signature diagnostic ions (Fig. 2). Within JEM Vol. 211, No. 6 
Article
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RvD1 increases expression of the adenosine  
2B receptor (A2BAR)
To ensure that leukocytes express receptors for netrin­1, we fo­
cused on the expression of A2BAR, Unc5B, neogenin, and the 
DCC. We further addressed whether RvD1 influences the ex­
pression of these receptors. The collected results showed that these 
receptors were expressed on human leukocytes; however, only the 
A2BAR is significantly induced by RvD1 (unpublished data).
Netrin-1 reduces human PMN chemotaxis  
and increases M efferocytosis: synergy with RvD1
Assessment  of  the  antiinflammatory  and  pro­resolving 
properties displayed by netrin­1 with human peripheral blood 
from arachidonic acid as well as docosahexaenoic acid­derived 
lipoxygenase products (Fig. 6 C). Levels of the chemoattractant 
LTB4 were significantly reduced (at 4 h) in mice given netrin­1 
compared with exudates from mice challenged with ZyA alone 
(Fig. 6 C). In contrast, at 4 h, PGD2 and PGE2 levels were sig­
nificantly elevated by netrin­1, whereas at 12 h netrin­1 signif­
icantly decreased both (Fig. 6 C). To translate this to human 
cells, we examined whether netrin­1 has an impact on human 
monocyte production of lipid mediators and performed LC­
MS/MS–based LM­profiling in human monocyte incubations. 
Netrin­1 increased the pro­resolving mediators LXA4, LXB4, 
RvD1, and RvE2, and decreased TNF­stimulated production 
of PGD2, PGE2, PGF2, and TXB2 (Fig. S1 and Table S2).
Figure 1.  Vagotomy delays resolution of 
inflammation. Mice were subjected to right-
sided cervical vagotomy or sham surgery. 
Netrin-1 mRNA (A) or protein (B) in the indi-
cated tissues was quantified by quantitative 
real-time RT-PCR or Western blot, respec-
tively. (C) Resolution indices as defined in 
(Bannenberg et al., 2005). (D and E) Mice were 
subjected to right-side cervical vagotomy or 
sham surgery and then injected i.p. with  
zymosan (1 mg/ml). Levels of TNF, IL-1, IL-6, 
KC, MIP-1, and HMGB1 in peritoneal lavage 
were measured by ELISA 4 h after zymosan 
injection. Acetylcholine (E) and netrin-1 levels 
(F, left) in peritoneal fluid at the indicated 
time points. Netrin-1 mRNA levels (F, right) in 
the peritoneal exudates were assessed by 
quantitative real-time RT-PCR at the indicated 
intervals. Results represent two independent 
experiments and are mean ± SEM, n = 6 mice 
per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001.1040 Netrin-1 activates resolution programs | Mirakaj et al.
Figure 2.  Vagotomy shifts exudate lipid mediator profile to proinflammatory. Mice were subjected to right-sided cervical vagotomy or sham surgery 
and then challenged with 1 mg zymosan. Peritoneal exudates were collected at the indicated intervals and lipid mediator profiles determined by lipid media-
tor metabololipidomics (see Materials and methods). (A) MRM chromatograms for the identified lipid mediators in murine exudates. a and b denote LTB4 iso-
mers: a = D6-trans-LTB4; b = 12-epi-D6-trans-LTB4. (B) Accompanying MS/MS spectra used for identification. (C) Levels of D-series resolvins, protectins, and 
maresins, lipoxins, and leukotriene B4, prostaglandin, and thromboxane measured at the indicated time points. Pie charts show the relative contribution of JEM Vol. 211, No. 6 
Article
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(Fig. 7 B) and did not display chemotactic activities on its   
own in this concentration range (n = 4). RvD1 also stops 
PMN migration (Kasuga et al., 2008). Because resolution of   
PMN revealed that netrin­1 reversed fMLP­induced CD62L 
shedding and CD11b neo­epitope exposure (Fig. 7 A). At con­
centrations as low as 1 nM, netrin­1 inhibited PMN migration 
Table 1.  Vagotomy shifts to proinflammatory lipid mediators-metabololipidomics
Q1 Q3 Inflam. time = 4 h Vagotomy + 
Inflam. time = 4 h
Average SEM Average SEM
pg/exudate pg/exudate
DHA bioactive metabolome
RvD1 375 215 27.7 ± 3.8 8.5 ± 2.1
RvD2 375 141 * *
RvD3 375 147 * *
RvD5 359 199 26.4 ± 5.7 60.1 ± 6.9
RvD6 359 159 4.8 ± 1.2 5.9 ± 2.2
4,14-diHDHA 359 101 10.5 ± 1.9 30.1 ± 3.2
MaR1 359 221 7.2 ± 2.1 9.0 ± 2.9
PD1 359 153 38.7 ± 8.2 90.5 ± 7.7
20-OH-PD1 359 153 * *
4-HDHA 343 101 151.8 ± 54.7 104.1 ± 16.9
7-HDHA 343 141 24.9 ± 6.9 21.9 ± 5.1
14-HDHA 343 205 10785.8 ± 3675.5 7852.7 ± 4296.4
17-HDHA 343 245 1249.6 ± 473.2 2859.1 ± 121.8
DHA 327 283 19793.0 ± 7673.2 18514.9 ± 689.9
AA bioactive metabolome
LXB4 351 115 4.7 ± 2.4 4.2 ± 0.7
LXB4 351 221 43.2 ± 18.5 60.6 ± 13.9
5,15-diHETE 335 115 82.4 ± 13.9 246.7 ± 4.7
LTB4 335 195 24.1 ± 5.7 113.8 ± 30.4
20-OH-LTB4 351 195 4.4 ± 1.2 6.2 ± 2.7
PGD2 351 189 79.1 ± 35.4 84.6 ± 7.9
PGE2 351 233 198.3 ± 19.6 295.0 ± 67.4
PGF2 353 193 86.9 ± 13.5 76.2 ± 19.9
TXB2 369 169 133.3 ± 9.4 266.5 ± 32.9
5-HETE 319 115 368.9 ± 92.9 364.1 ± 95.0
12-HETE 319 179 14681.2 ± 3618.1 11572.2 ± 4095.4
15-HETE 319 219 857.2 ± 202.8 660.4 ± 212.5
AA 303 259 38.8 ± 7.2 26.2 ± 4.7
EPA bioactive metabolome
RvE1 349 195 * *
RvE2 333 199 * *
LXA5 349 115 * *
LXB5 349 221 * *
5,15-diHEPE 333 115 * *
5-HEPE 317 115 20.2 ± 4.5 12.8 ± 1.7
12-HEPE 317 179 1176.1 ± 147.1 801.9 ± 116.0
18-HEPE 317 259 694.9 ± 66.2 354.6 ± 124.0
15-HEPE 317 219 16.3 ± 4.5 17.9 ± 2.4
EPA 301 257 3.5 ± 2.5 8.6 ± 0.7
Individual lipid mediators and precursor/pathway markers at: Q1, M-H (parent ion); and Q3, diagnostic ion in the MS/MS (daughter ion) along with mean ± SEM values for 
each of the mediators (pg/exudate) identified in the 4-h exudates. Detection limit, 1 pg. *, below limits.
 
lipid mediators. Blue shading denotes proresolving and red shading denotes pro-inflammatory Results are expressed as mean ± SEM; n = 4 mice per time 
point for two independent experiments. *, P < 0.05; **, P < 0.01 versus inflammation mice at the respective interval.1042 Netrin-1 activates resolution programs | Mirakaj et al.
endothelial cells (HMEC) and epithelial A549 cells exposed 
to netrin­1. With both cell types, netrin­1 significantly in­
creased the expression of mRNA for human GPR32 and 
ALX/FPR2 and increased protein expression for both recep­
tors (unpublished data).
DISCUSSION
The present results demonstrate a novel vagus­resolution cir­
cuit that involves pro­resolving lipid mediators and netrin­1. 
Netrin­1 reduces local injury and inflammatory responses 
(Wu et al., 2001; Mirakaj et al., 2010; 2011a,b). Here, we find 
that netrin­1 stimulates resolution mechanisms and production 
of resolvins (Figs. 3 and 7) and, thus, by definition (Serhan, 
2011) is an innate immune system resolvent. Netrin­1 decreased 
PMN recruitment in vitro and in vivo, and the resolution in­
terval was significantly shortened as a quantitative measure of 
resolution. Netrin­1 also increased nonphlogistic mononuclear 
cell recruitment and M uptake of apoptotic PMNs. Together, 
these findings indicate that local netrin­1 is actively involved 
in the resolution mechanisms of acute inflammation in both 
lung and abdominal tissues, stimulating production of pro­
resolution lipid mediators, defining a novel neuronal­resolvin 
circuit regulated by the vagus nerve.
inflammation is a dynamic process with one of the key steps 
being the clearance of apoptotic PMN by M (Serhan and 
Savill, 2005), we next assessed the ability of netrin­1 to regu­
late this pro­resolving mechanism. Netrin­1 stimulated the 
uptake of apoptotic PMN by human M in a dose­dependent 
manner (Fig. 7 C). These results were further corroborated   
in vivo, where netrin­1 enhanced M clearance of apoptotic 
PMN (unpublished data) in mice.
Co­incubations  of  netrin­1  and  RvD1  with  primary 
human M stimulated efferocytosis to levels above those dis­
played by either alone (Fig. 7 D). The actions of netrin­1 on 
M efferocytosis and phagocytosis were 12/15­LOX depen­
dent because 12/15­LOX/ mice displayed reduced effero­
cytosis (Fig. 7 E) that was also reduced >85% with phagocytosis 
of fluorescently labeled opsonized zymosan (not depicted). 
Because 12/15­LOX in mice is the enzymatic first step to 
RvD1 production (Serhan and Petasis, 2011), these results 
demonstrate the requirement of this LOX–resolvin pathway 
for netrin­1 actions in resolution.
Because RvD1 activates two GPCRs present on human 
M, the lipoxin receptor (ALX/FPR2) and DRV1/GPR32 
(Krishnamoorthy et al., 2010), we next evaluated mRNA ex­
pression for these two receptors in both human microvascular 
Figure 3.  RvD1 rescues hyperinflammation in vagotomized mice. Vagotomized or sham-operated control mice were injected i.p. with zymosan A 
(ZyA) and subsequently with RvD1 (RvD1). Peritoneal lavages were collected at indicated time points. (A) Total leukocytes were enumerated by light mi-
croscopy. PMN, classical monocytes, and nonclassical monocytes were determined by flow cytometry. (B) TNF, IL-6, KC, MIP-1, and HMGB1 were mea-
sured in exudates by ELISA. Results are mean ± SEM, n = 6 per group for two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM Vol. 211, No. 6 
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leukocyte migration and tissue infiltration (Nathan, 2002; Serhan, 
2007). The circulation of leukocytes and the integrity of the 
vascular endothelial barrier are known impediments to aber­
rant infiltration (Muller, 2002). On initiation of inflammation, 
the resolution phase is concomitantly activated, which is a 
highly coordinated and biochemically active process that was 
once thought to be passive at the tissue level, i.e., simple dilu­
tion of the initiating chemical mediators (Bannenberg et al., 
2005; Serhan and Savill, 2005; Serhan and Petasis, 2011). The 
process of resolution is controlled in part by the biosynthesis of 
endogenous chemical lipid mediators that are local autacoids 
stimulating,  as  novel  agonists,  pro­resolving  mechanisms 
(Serhan and Petasis, 2011; Dalli and Serhan, 2012).
During  the  acute  inflammatory  response,  leukocytes 
(Nathan, 2002) diapedese and migrate to the site of inflam­
mation guided by gradients of chemical signals, including me­
diators such as chemokines (Serhan et al., 2008; Tabas and Glass, 
2013) and lipid mediators (Serhan and Savill, 2005; Serhan and 
Petasis, 2011; Samuelsson, 2012). These are critical components 
and steps in the initial response and host defense. If in excess or 
persistent, the initial inflammatory response that does not ter­
minate or resolve can lead to collateral tissue destruction with 
chronicity and eventual loss of functional organ integrity (Serhan 
and Savill, 2005; Serhan et al., 2008). Because excessive leuko­
cyte migration into peripheral tissues can have serious con­
sequences, checkpoints exist at several levels to regulate local 
Figure 4.  Netrin-1 stimulates resolution via RvD1. 
Resolution indices were used as previously defined (Bannenberg 
et al., 2005), including max (maximal PMN), Tmax (time point 
when PMNs reach max), T50 (time point corresponding to 
50% reduction), and Ri (resolution interval, the time interval 
from max to 50% reduction point [i.e., T50-Tmax]). (A) Mice 
were injected i.p. with 1 mg of zymosan A (ZyA) and, sub-
sequently, i.v. with either vehicle or recombinant netrin-1  
(1 µg). Peritoneal exudates were collected at indicated time 
intervals and neutrophils (PMN) were enumerated by using 
light microscopy and flow cytometry. (B) Mice were treated 
as in panel A, and netrin-1 was given at the peak of inflam-
mation (4h after ZyA). (C) Ntn1+/+ were injected i.p. with ZyA 
(1 mg) and subsequently with RvD1 (1 µg/mouse). Recruited 
leukocytes were enumerated at indicated time points.  
(D) Ntn1+/+ and Ntn1+/ mice were injected i.p. with ZyA 
(1mg) and subsequently with vehicle or RvD1 (1 µg/mouse), 
and peritoneal exudates were collected at indicated time 
intervals. Results in A–D represent 2 independent experi-
ments with n = 4–6 mice per treatment per time point  
expressed as mean.1044 Netrin-1 activates resolution programs | Mirakaj et al.
2001; Serhan, 2007). Accordingly, in the early inflammatory 
events we found that netrin­1 lowered LTB4, a primary che­
moattractant, and temporally regulated both PGD2 and PGE2, 
which are key in mediator class switching in resolution (Levy 
et al., 2001). For the pro­resolving mediators, both RvD5 and 
PD1 exudate levels were increased by netrin­1. We also found 
a significant decrease in endogenous netrin­1 at 4 h in in­
flammatory exudates that were enhanced in early resolution 
(Fig. 3). These results likely reflect the local activation of pro­
resolving signals by netrin­1 because both RvD5 and PD1 
were dramatically increased in vivo.
In addition to limiting PMN migration, resolution of in­
flammation is defined by an increase in the local M uptake 
of apoptotic PMNs and their removal (Bannenberg et al., 
2005; Serhan and Savill, 2005). Netrin­1 decreased PMN mi­
gration (Fig. 4 C) and increased the uptake of apoptotic PMN. 
Both RvD1 and netrin­1 enhanced efferocytosis, giving sub­
stantial synergy. Recently, Liu et al. (2012) demonstrated that 
in neuronal degenerative diseases such as amyotrophic lateral 
sclerosis, with human M from these patients, RvD1 potently 
reduced the production of inflammatory cytokines from these 
patients. In this context with human cells, RvD1 activates both 
the GPCR lipoxin receptor (ALX/FPR2) and the human 
GPR32 RvD1 receptor denoted DRV1 (Serhan and Petasis, 
2011), and its leukocyte actions are abolished in receptor­
deficient mice (Norling et al., 2012). In the present experi­
ments, netrin­1 significantly increased the mRNA and protein 
expression of both ALX/FPR2 and GPR32 receptors in 
human endothelial and epithelial cells. Collectively, these re­
sults demonstrate novel interactions between netrin­1 and 
resolvins, each controlled by the vagus nerve, that are essential 
mechanisms in the resolution of acute inflammation.
In the present experiments, we questioned whether vagot­
omy impacts resolution processes and found that netrin­1 is an 
endogenous pro­resolution signal. Netrin­1, from the results 
herein, fulfills the definition of an immunoresolvent (Serhan, 
2011) via its interactions with leukocytes and pro­resolving 
lipid mediators in the context of acute inflammation and tissue 
injury. Our results also reveal that mice with partial netrin­1 
deficiency (Ntn1+/) displayed increased leukocyte infiltration, 
and RvD1 was less effective at limiting PMN entry compared 
with WT littermates, illustrating the bidirectional relationship 
between netrin and resolvins. This finding is consistent with 
the ability of netrin­1 to dampen the inflammatory response 
in the initial phase of an acute inflammation. Using murine 
peritonitis and resolution indices (Bannenberg et al., 2005), 
we found that netrin­1 decreased PMN recruitment and 
protein levels in exudates during the course of inflammation. 
Netrin­1 also reduced proinflammatory cytokines including 
TNF and up­regulation of antiinflammatory cytokine IL­10 
(Fig. 1). Importantly, netrin­1 administered at the peak of 
PMN  infiltration  during  inflammation  significantly  de­
creased PMN numbers at later time intervals (Fig. 4). This role 
of netrin­1 is embedded into a neuronal reflex circuit via 
the vagus nerve that enables it to influence the resolution   
of inflammation.
During the initial events in inflammation, classic eico­
sanoids including prostaglandins and leukotrienes play pivotal 
roles as local mediators ( Serhan and Petasis, 2011; Samuelsson, 
2012). The prostaglandins PGE2 and PGD2 switch the me­
diators produced, an event called mediator class switching, 
which involves the biosynthesis of SPM, which actively limits 
inflammation by cessation of PMN influx and enhances 
M­mediated clearance to promote resolution (Levy et al., 
Figure 5.  Vagotomy reduces netrin-1 expression. Animals were subjected to unilateral vagotomy or a comparable sham surgical procedure and 
netrin-1 and neurofilament expression in lungs was assessed by immunofluorescence. (A) Colocalization (green) of netrin-1 with the neuronal marker 
neurofilament (red) and yellow in the merged image. Bars, 100 µm. Results are representative of two separate experiments (n = 3 mice per group).  
(B) Leukocytes isolated from human peripheral blood were incubated with an antibody against netrin-1, CD15, CD14, CD68, CD3, CD19, and the expres-
sion of indicated marker was measured by flow cytometry. Results are representative of two separate experiments (from n = 3 healthy donors).JEM Vol. 211, No. 6 
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be relevant in other inflammation­associated diseases and 
organ fibrosis.
Combining pro­resolution mediators, e.g., RvD1, together 
with the axonal guidance molecule netrin­1 appears to be a 
useful approach to activate resolution of inflammation and pro­
tection of organs from injury from within, events controlled by 
vagus nerve as documented herein. Moreover, our present find­
ings demonstrate that netrin­1 is a direct agonist of resolution, 
i.e., shortening the resolution interval, activating pro­resolving 
lipid mediator production, limiting PMN influx, and increasing 
M efferocytosis of apoptotic PMN. The finding that vagus 
Along these lines, netrin­1 promotes atherosclerosis by 
inhibiting the emigration of M from plaques (van Gils   
et al., 2012), supporting a potential failure of local vascular 
resolution mechanisms contributing to atherosclerosis (Merched 
et al., 2008). Because netrin­1 evokes both positive and neg­
ative axonal migration, as well as actions with PMN, mono­
cytes, and M, netrin­1 may have divergent roles in regulating 
the extent of inflammation and its resolution that depend 
on the organ. Given the ability of netrin­1 to stop and tem­
porally limit PMN recruitment, stimulate resolution, and 
SPM production (e.g., resolvins; Fig. 2), netrin­1 may also 
Figure 6.  Netrin-1 enhances endogenous pro-resolving lipid mediators. Mouse peritonitis was initiated by i.p. injection of 1 mg of zymosan A 
(ZyA) and i.v. with recombinant netrin-1 (1 µg), and peritoneal exudates were collected at 4 and 12 h. Lipid mediator profiles were determined by lipid 
mediator metabololipidomics. (A) Representative MRM chromatograms for identified lipid mediators in murine self-resolving exudates and (B) MS/MS 
spectra. (C) Bioactive lipid mediators and precursor/pathway marker levels in the individual exudate at the indicated intervals as determined by MRM (see 
Materials and methods for details). Results are mean ± SEM and are representative of two independent experiments. n = 3–5 mice per group. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.1046 Netrin-1 activates resolution programs | Mirakaj et al.
nerve signals proteins and pro­resolving lipid mediators in­
volved in axonal migration that carry additional functions out­
side the central nervous system opens new directions in our 
appreciation of the resolution of inflammation within inner­
vated organs. These may also be useful in designing new thera­
peutic approaches for inflammation associated with surgery 
and/or traumatic tissue injury.
MATERIALS AND METHODS
Vagotomy. C57BL/6 mice were subjected to sham surgery, unilateral   
vagotomy, zymosan A administration, or a combination of vagotomy and   
zymosan A application. To inhibit the cholinergic antiinflammatory pathway, 
mice were subjected to unilateral (right side) cervical vagotomy or sham sur­
gery 7 d before induction of peritonitis. A unilateral vagotomy was chosen 
because bilateral vagotomy is lethal in mice. Animal protocols were approved 
by the Regierungspräsidium Tübingen. Ntn1+/+ and Ntn1+/ animals were bred 
on a CD1 background (Rosenberger et al., 2009). In brief, mice were anes­
thetized and a ventral cervical midline incision was performed to expose the 
right cervical vagus trunk, which was ligated with a 4–0 silk suture and then 
divided. 7 d later, peritoneal lavages and organ tissues were obtained at 0, 4, 
12, 24, and 48 h after initiating peritonitis.
Murine  peritonitis.  Mouse  protocols  were  approved  by  the  Harvard 
Medical Area Standing Committee on Animals. C57BL/6 mice were in­
jected i.p. with 1 ml zymosan A (ZyA; 1 mg/ml; Sigma­Aldrich) and sub­
sequently with vehicle (saline plus 0.2% BSA) or 1 µg murine recombinant 
netrin­1 (R&D Systems) in 150 µl total volume. Recruited leukocytes 
were obtained at time points of 4, 12, 24, 48, and 72 h by peritoneal lavage 
with PBS solution containing 10 U/ml unfractionated heparin (Mirakaj et al., 
2011b). Collected cells were washed, suspended in Hanks’ balanced salt solu­
tion (2 ml), counted and cytospin samples prepared. All reagents used were 
endotoxin­free.
Proteins: transcriptional and protein analysis. For Western blot analysis, 
animal samples were homogenized, normalized for protein levels, and applied 
to SDS containing polyacrylamide gels. Antibodies used for Western blotting 
included polyclonal rabbit anti–netrin­1 (Santa Cruz Biotechnology, Inc.) for 
murine netrin­1 analysis. Actin was stained using polyclonal rabbit anti­Actin 
(Santa Cruz Biotechnology, Inc.). Blots were washed, and species­matched, 
peroxidase­conjugated secondary antibody (Santa Cruz Biotechnology, Inc.) 
was added. Labeled bands from washed blots were detected by enhanced che­
miluminescence (GE Healthcare).
Differential leukocyte counts, FACS analysis, and cytokines. Exudate 
cells from murine peritonitis were prepared for determining cellular compo­
sition by staining cells with APC­conjugated anti–mouse Ly6G (eBiosci­
ence) and FITC conjugated anti­mouse Ly6C (BioLegend) for 30 min on 
ice. After washing, cell pellets were suspended in FACS buffer and analyzed 
using flow cytometry using BD FACS Diva Software. Cytokines were mea­
sured in the peritoneal exudates obtained from mice using standard ELISA 
(R&D Systems and Biocompare).
Resolution indices. The key processes in the resolution of acute inflamma­
tion can be quantified using resolution indices as defined in (Bannenberg   
et al., 2005) and used herein as follows: magnitude (max, Tmax), the time point 
(Tmax) after T0 challenge or T0 injury when neutrophil numbers in tissues or 
exudates reach maximum (max); duration (R50, T50), the time point (T50) 
when the PMNs reduce and nonphlogistic monocyte numbers intercept 
Figure 7.  Netrin-1 reduces human PMN activation and increases 
M efferocytosis: Synergy with RvD1 pathway. (A) Isolated human 
PMN were incubated with either fMLP or netrin-1 for 30 min and the 
expression of CD11b (neo-epitope) and CD62L on PMN was measured by 
flow cytometry. (B) Isolated human PMN were placed on chemotaxis 
slides and exposed for 2 h to either fMLP or netrin-1. The cell migration 
was monitored for a 10-min period and analyzed using Image Pro Plus 7 
software. (C) M differentiated from peripheral blood monocytes were 
incubated with indicated concentrations of netrin-1. Carboxyfluorescein 
diacetate-labeled apoptotic PMN were added at 1:3 ratio (M:PMN), and 
the rate of the efferocytosis was determined after 1 h by measurement of 
fluorescence. (D) M differentiated from peripheral blood monocytes 
were incubated with netrin-1 in the absence or presence of RvD1. The 
degree of efferocytosis was performed using a fluorescent plate reader. 
(E) Peritoneal M from WT or 12/15LO/ mice were incubated with the 
indicated concentrations of netrin-1 (15 min, 37°C), the fluorescently 
labeled apoptotic PMN were added and the degree of efferocytosis was 
assessed after 1 h (37°C) using a fluorescent plate reader (see Materials 
and methods). Results are representative of five independent experiments 
(n = 5), mean ± SEM, in A–D. In E, results are representative of three inde-
pendent experiments (n = 3 mice); *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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as primary antibody. Rabbit IgG Isotype (Santa Cruz Biotechnology, Inc.) 
was used for negative control. FITC­conjugated goat anti–rabbit (Dianova) 
was used as secondary antibody. DAPI (4’, 6­diamidino­2­phenylindol; In­
vitrogen) was used for nuclear counter staining. For neuronal staining, mouse 
anti–neurofilament (Abcam) was used and Alexa Fluor 647–conjugated goat 
anti–chicken (Abcam) was applied as secondary antibody. Fluorescence mi­
croscope LSM 510 Meta (Carl Zeiss) was used for imaging.
Human M efferocytosis. For differentiation of M, peripheral blood 
monocytes were isolated from human leukapheresis collars from the Chil­
dren’s Hospital Boston Blood Bank and cultured in RPMI with 10 ng/ml 
human recombinant GM­CSF (R&D Systems; 37°C for 7 d). To prepare 
apoptotic PMN, human PMNs obtained from peripheral blood were isolated 
and labeled with carboxyfluorescein diacetate (10 µM, 30 min at 37°C; Invit­
rogen) and allowed to undergo apoptosis in serum­free RPMI for 16–18 h. 
M (0.106 cells/well) were incubated with human recombinant netrin­1 
(R&D Systems) in the presence or absence of RvD1 (1 nM) Boc2 peptide 
(104 M; Santa Cruz Biotechnology, Inc.; 15 min at 37°C). Apoptotic PMNs 
were added at 1:3 ratio (M/PMN) with phagocytosis incubations per­
formed at 37°C for 60 min, and fluorescence was determined by using a fluor­
escent plate reader (SpectraMax; Molecular Devices).
Transcriptional and protein analysis. Transcriptional analysis of netrin­1 
was  performed  using  sense  primer  5­GAGCGGGGGAGTCTGTCT­3 
and 5­TGGTTTGATTGCAGGTCTTG­3 antisense primer. Samples were 
controlled for 18S using the following primers: sense, 5­GTAACCCGTT­
GAACCCCATT­3;  antisense,  5­CCATCCAATCGGTAGTAGCG­3. 
Semiquantitative analysis of mRNA was performed using real­time PCR 
(iCycler; Bio­Rad Laboratories).
Data analysis. Results are expressed as mean ± SEM. Statistical analyses 
were performed using the Student’s t test, one–way ANOVA, or two–way 
ANOVA was considered statistically significant.
Online supplemental material. Table S1 shows the lipid mediator levels 
in self­resolving exudates of vagotomized and sham operated mice. Fig. S1 
and Table S2 show that Netrin­1 stimulates endogenous pro­resolving lipid 
mediators with human monocytes. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20132103/DC1.
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